Cantor Fitzgerald Initiates Coverage On Nuvectis Pharma with Overweight Rating

Benzinga Newsdesk www.benzinga.com Neutral 59.6%

Neg 0% Neu 59.6% Pos 0%

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Overweight rating.